# Melasma: Hormonal Influences and Treatment Challenges

## Introduction

Melasma is a common, acquired, symmetric hyperpigmentary disorder that disproportionately affects women of reproductive age with Fitzpatrick skin types III-V. Its chronic, relapsing nature and resistance to treatment make it one of the most frustrating conditions for both patients and clinicians. An understanding of the complex interplay between ultraviolet radiation, hormonal influences, and vascular factors is essential for developing effective, multimodal treatment strategies.

## Epidemiology

The prevalence of melasma varies widely, from 1% in general populations to 50% in high-risk groups (pregnant women, women on oral contraceptives in sun-exposed regions). It predominantly affects women (90%), with men accounting for approximately 10% of cases. Skin types III through V have the highest prevalence, particularly among Hispanic/Latina, South Asian, Middle Eastern, East Asian, and African populations. The most important modifiable risk factor is UV exposure, followed by pregnancy ("mask of pregnancy" or chloasma), oral contraceptives, hormone replacement therapy, and genetic predisposition (family history is positive in 40 to 60%).

## Pathogenesis

### UV Radiation

UV radiation is the single most important exacerbating factor, and both **UVA and visible light** contribute to pigmentation. UV radiation stimulates melanogenesis through direct activation of the **melanocortin 1 receptor (MC1R)** on melanocytes via alpha-MSH, upregulation of **stem cell factor (SCF)** and **endothelin-1 (ET-1)** by keratinocytes, and activation of **opsin-3**, a blue light photoreceptor on melanocytes. **Visible light (400 to 700 nm)**, particularly blue light, induces long-lasting pigmentation in darker skin types through opsin-3-mediated calcium signaling.

### Hormonal Influences

**Estrogen and progesterone** directly stimulate melanogenesis. Melanocytes express **estrogen receptors (ER-alpha and ER-beta)** and **progesterone receptors**. Estrogen upregulates **tyrosinase**, **TRP-1**, **TRP-2**, and **MITF**, the master transcription factor for melanogenesis. Progesterone has independent pro-melanogenic effects. During pregnancy, rising estrogen and progesterone levels trigger melasma in 50 to 70% of pregnancies, and the condition may persist postpartum. Oral contraceptives cause melasma in 20 to 30% of users. Thyroid dysfunction has an emerging association, as thyroid hormones may modulate melanogenesis.

### Vascular Component

**Increased vascularity** is a key and underappreciated feature of melasma. Lesional skin shows elevated **VEGF expression** and **increased dermal vascularity** compared to adjacent normal skin. Vascular endothelial cells produce **ET-1** and **SCF**, which promote melanogenesis, creating a paracrine loop between blood vessels and melanocytes. This vascular component explains why treatments targeting only melanocytes have limited success.

### Basement Membrane Disruption

**Pendulous melanocytes** (melanocytes dropping into the dermis through a disrupted basement membrane) are a histopathologic feature of melasma. Basement membrane zone disruption facilitates melanin "fall" into the dermis, creating the dermal component of melasma that is resistant to topical therapy.

### Mast Cell and Inflammatory Involvement

Increased mast cell density in lesional skin leads to release of **tryptase**, **histamine**, and **SCF**, all of which promote melanogenesis. Solar elastosis and chronic low-grade UV-induced inflammation contribute to a microenvironment that favors pigmentation.

## Clinical Features

### Distribution Patterns

The **centrofacial** pattern (65%) involves the forehead, cheeks, nose, upper lip, and chin and is the most common. The **malar** pattern (20%) is confined to the cheeks and nose. The **mandibular** pattern (15%) involves the jawline and chin and is often associated with hormonal triggers. **Extrafacial melasma** affecting the forearms, upper chest, and back is increasingly recognized.

### Clinical Assessment

Melasma presents as symmetric, brown-to-gray-brown patches with irregular borders on sun-exposed facial skin. **Wood's lamp examination** helps classify the pigment depth: **epidermal melasma** shows pigment enhancement under Wood's lamp (365 nm), suggesting more superficial and potentially more treatment-responsive disease; **dermal melasma** shows minimal enhancement, indicating deeper pigment that is less treatment-responsive; and **mixed melasma** shows variable enhancement and is the most common clinical type. **Dermoscopy** reveals brown pseudo-reticular or arcuate structures (epidermal), gray-blue dots and granules (dermal), and telangiectasias (vascular component). The **Melasma Area and Severity Index (MASI)** is a standardized scoring tool assessing area, darkness, and homogeneity.

<image>Clinical photographs showing the three distribution patterns of melasma on faces of varying Fitzpatrick skin types: centrofacial pattern affecting forehead, cheeks, nose, and upper lip; malar pattern confined to the cheeks; and mandibular pattern along the jawline, with corresponding Wood's lamp enhancement images</image>

## Treatment

### Photoprotection (Foundation of All Therapy)

**Broad-spectrum sunscreen** with SPF 30 or higher and UVA protection (zinc oxide, titanium dioxide, or modern organic filters) is essential. **Tinted sunscreen with iron oxides** is a critical addition because iron oxides block **visible light**, which standard sunscreens do not. Studies demonstrate that tinted sunscreen alone can produce clinically meaningful improvement in melasma. Sunscreen should be reapplied every 2 hours during outdoor exposure, and hats and sun avoidance are complementary measures. **Photoprotection without visible light protection is incomplete**.

### First-Line Topical Therapy

#### Triple Combination Cream (Tri-Luma)

**Hydroquinone 4% plus tretinoin 0.05% plus fluocinolone acetonide 0.01%** is the most effective single topical agent for melasma. Hydroquinone inhibits tyrosinase, tretinoin accelerates epidermal turnover and enhances hydroquinone penetration, and fluocinolone reduces inflammation. It is applied nightly for 8 to 12 weeks as an initial course, then transitioned to maintenance. It is superior to any individual component alone. Adverse effects include irritation, erythema, and dryness, with risk of **exogenous ochronosis** (blue-gray dermal pigmentation) with prolonged, unsupervised hydroquinone use, so continuous use should be limited to 3 to 6 months.

#### Hydroquinone Monotherapy

**4% hydroquinone** is the gold standard single depigmenting agent, applied twice daily with results visible in 4 to 8 weeks. It should be cycled with hydroquinone-free intervals to reduce ochronosis risk. Over-the-counter 2% formulations are less effective but safer for long-term use.

| Agent | Mechanism | Application | Key Notes |
|-------|-----------|-------------|-----------|
| Triple combination (Tri-Luma) | Tyrosinase inhibition + turnover + anti-inflammatory | Nightly x 8–12 weeks | Most effective single topical; cycle to avoid ochronosis |
| Hydroquinone 4% | Tyrosinase inhibitor | BID x 8–12 weeks (cycle) | Gold standard; limit continuous use to 3–6 months |
| Oral tranexamic acid 250 mg BID | Antifibrinolytic; reduces keratinocyte-melanocyte signaling | 3–6 months | Addresses vascular component; avoid in thromboembolism |
| Azelaic acid 15–20% | Tyrosinase inhibitor; anti-inflammatory | BID | Safe in pregnancy; good for maintenance |
| Topical tranexamic acid 3–5% | Inhibits plasminogen-keratinocyte interaction | BID | Excellent safety profile |
| Cysteamine 5% | Antioxidant; multi-step melanogenesis inhibition | Daily | Growing evidence |
| Tinted sunscreen (iron oxides) | Blocks visible light | Daily | Essential; standard sunscreens miss visible light |

### Second-Line and Adjunctive Topical Agents

**Azelaic acid 15 to 20%** inhibits tyrosinase and has anti-inflammatory properties; it is safe in pregnancy and useful for maintenance. **Cysteamine 5% cream** is an antioxidant that inhibits melanogenesis at multiple steps, with growing evidence of efficacy. **Tranexamic acid (topical 3 to 5%)** inhibits plasminogen-keratinocyte interactions and reduces UV-induced melanogenesis with an excellent safety profile. **Topical retinoids** (tretinoin 0.025 to 0.05%, adapalene) enhance turnover and facilitate depigmenting agent penetration, though irritation limits use in sensitive skin. **Vitamin C (L-ascorbic acid 10 to 20%)** is an antioxidant that reduces melanin synthesis and is best used in combination. **Kojic acid 2%**, **arbutin**, and **niacinamide 4%** are milder alternatives for maintenance or patients intolerant of hydroquinone. **Methimazole 5% cream** is an off-label option that inhibits peroxidase activity in melanocytes and has shown safety and efficacy in small studies.

### Oral Tranexamic Acid

Oral tranexamic acid has emerged as a standard therapy for moderate-to-severe or refractory melasma. The typical dose is **250 mg twice daily**, lower than doses used for hemostasis. Its mechanism as an antifibrinolytic agent inhibits **plasmin-mediated release of arachidonic acid** and reduces **keratinocyte-melanocyte signaling**. It also decreases mast cell activity and VEGF expression, addressing the vascular component. Multiple RCTs demonstrate significant reduction in MASI scores. Treatment duration is typically 3 to 6 months, with relapse common after discontinuation. Adverse effects at low doses are generally mild (GI upset, headache), with theoretical thromboembolic risk that is extremely rare at low doses. It should be avoided in patients with active thromboembolism, history of DVT/PE, or hypercoagulable states. Screening with CBC and hepatic/renal function should precede initiation.

### Procedural Treatments

**Chemical peels** with glycolic acid (30 to 70%), salicylic acid (20 to 30%), or lactic acid serve as adjuncts to topical therapy, but deep peels should be avoided in darker skin due to high PIH risk. **Microneedling** enhances transdermal drug delivery, and combination with tranexamic acid or vitamin C shows promise. **Laser therapy** is **highly controversial in melasma** due to risk of PIH and rebound hyperpigmentation, especially in darker skin. Low-fluence Q-switched Nd:YAG (1064 nm, "laser toning") has some evidence of efficacy but high relapse and rebound rates and is not recommended as monotherapy. Fractional non-ablative lasers (1550 nm) have limited and inconsistent evidence. Vascular lasers (PDL, IPL) may address the vascular component specifically and represent an emerging area of study. The general consensus is that **lasers should be used cautiously and only as adjuncts to comprehensive medical therapy**.

<image>Multimodal treatment algorithm for melasma showing: foundation of broad-spectrum plus iron oxide tinted sunscreen, first-line triple combination cream with cycling protocol, adjunctive oral tranexamic acid for refractory cases, and maintenance therapy sequence with non-hydroquinone agents to prevent relapse</image>

## Maintenance and Relapse Prevention

**Melasma is a chronic condition**, and relapse is the rule, not the exception. **Maintenance therapy** after initial improvement involves rotating between non-hydroquinone agents (azelaic acid, cysteamine, vitamin C, niacinamide, tretinoin). **Year-round photoprotection** with tinted sunscreen is non-negotiable. **Hormonal management** includes discontinuation of oral contraceptives if feasible with discussion of alternatives. Setting **realistic expectations** is important: significant improvement (not cure) is the achievable goal, and managing expectations reduces patient frustration.

## Key Clinical Pearls

Tinted sunscreen with iron oxides is essential because visible light drives melasma in darker skin types and standard sunscreens do not block visible light. The vascular component of melasma is increasingly recognized and explains why anti-melanocyte therapies alone are insufficient. Oral tranexamic acid at low doses has emerged as one of the most effective systemic treatments and addresses multiple pathogenic factors. Triple combination cream remains the most effective topical therapy but must be cycled to prevent ochronosis. Laser treatment of melasma carries significant risk of worsening and should never be used as first-line monotherapy.

## References

1. Passeron T, Picardo M. Melasma, a photoaging disorder. *Pigment Cell Melanoma Res*. 2018;31(4):461-465.
2. Handel AC, Miot LDB, Miot HA. Melasma: a clinical and epidemiological review. *An Bras Dermatol*. 2014;89(5):771-782.
3. Bala HR, Lee S, Wong C, et al. Oral tranexamic acid for the treatment of melasma: a review. *Dermatol Surg*. 2018;44(6):814-825.
4. Rajanala S, Maymone MBC, Vashi NA. Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies. *Dermatol Online J*. 2019;25(10):13030.